Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) FCF Margin (2016 - 2025)

Historic FCF Margin for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to 43.98%.

  • United Therapeutics' FCF Margin rose 38300.0% to 43.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 47.05%, marking a year-over-year increase of 51300.0%. This contributed to the annual value of 37.55% for FY2024, which is 54300.0% up from last year.
  • As of Q3 2025, United Therapeutics' FCF Margin stood at 43.98%, which was up 38300.0% from 16.22% recorded in Q2 2025.
  • United Therapeutics' 5-year FCF Margin high stood at 7200.0% for Q4 2023, and its period low was 3221.52% during Q4 2024.
  • Moreover, its 5-year median value for FCF Margin was 36.5% (2021), whereas its average is 240.82%.
  • In the last 5 years, United Therapeutics' FCF Margin skyrocketed by 71819500bps in 2023 and then tumbled by -104215200bps in 2024.
  • Over the past 5 years, United Therapeutics' FCF Margin (Quarter) stood at 25.05% in 2021, then decreased by -28bps to 18.05% in 2022, then surged by 39796bps to 7200.0% in 2023, then tumbled by -145bps to 3221.52% in 2024, then soared by 101bps to 43.98% in 2025.
  • Its FCF Margin was 43.98% in Q3 2025, compared to 16.22% in Q2 2025 and 48.63% in Q1 2025.